Christopher Li

Research Professor, Epidemiology



MD Medicine, University of California (San Francisco), 2000
PhD Epidemiology, University of Washington, 2003
MPH Epidemiology, University of Washington, 2000



Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave N., M4-C308
P.O. 19024
Seattle, WA 98109
View Website »

Research Interests

Dr. Li is a cancer epidemiologist based at the Fred Hutchinson Cancer Research Center with research projects spanning cancer early detection/screening, etiology, and survivorship. He has significant expertise in cancer epidemiology and substantial experience in the design, leadership, and completion of multidisciplinary studies of cancer. Current research projects include: 1. A large population-based study of different molecular subtypes of breast cancer aimed at elucidating their risk factors and identifying novel subtype-specific tumor markers useful for predicting risk of disease recurrence (DOD Collaborative Innovator Award); 2. A nested case-control study of women with DCIS who did and did not go on to develop a second breast cancer aimed at developing novel epidemiologic, clinical, and molecular approaches for guiding clinical decision making for DCIS patients (R01); 3. Discovering and validating novel blood-based markers useful for the early detection of breast, colorectal, and ovarian cancers (U01); 4. Characterizing risk factors for second primary breast, lung, colorectal, and endometrial cancers among breast cancer survivors (R01); and 5. Discovering and validating novel biomarkers useful for assessing risk of recurrence among colorectal cancer survivors (R01 and U01). Selected leaderships activities include: 1. Serving as the co-PI of the Cancer Surveillance System (CSS), the Seattle-Puget Sound Surveillance, Epidemiology and End Results (SEER) cancer registry, 2. Chairing the DOD Breast Cancer Research Program’s Integration Panel (FY 2017), and 3. Co-chairing the 2017 AACR Conference on the Science of Cancer Health Disparities.

Recent Publications (PubMed)

Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients.
Am J Cancer Res 12(10): 4789-4801
Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL, Ulrich CM

Associations of individual and combined physical activity and body mass index groups with pro-inflammatory biomarkers among colorectal cancer patients.
(2022 Sep 13)
Cancer Epidemiol Biomarkers Prev
Himbert C, Warby CA, Gigic B, Ose J, Lin T, Viskochil R, Peoples AR, Ashworth A, Schrotz-King P, Scaife CL, Cohan JN, Jedrzkiewicz J, Schirmacher P, Grady WM, Cohen SA, Krane M, Figueiredo JC, Toriola AT, Siegel EM, Shibata D, Round JL, Huang LC, Li CI, Schneider M, Ulrich A, Hardikar S, Ulrich CM

ASO Visual Abstract: Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen Receptor-Positive Breast Cancer.
(2022 Oct)
Ann Surg Oncol 29(11): 7204-7205
Flanagan MR, Doody DR, Voutsinas J, Wu Q, Banda K, Sharifi N, Li CI, Gadi VK

Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda.
(2022 Aug 2)
Cancer Epidemiol Biomarkers Prev 31(8): 1521-1531
Beaber EF, Kamineni A, Burnett-Hartman AN, Hixon B, Kobrin SC, Li CI, Oliver M, Rendle KA, Skinner CS, Todd K, Zheng Y, Ziebell RA, Breslau ES, Chubak J, Corley DA, Greenlee RT, Haas JS, Halm EA, Honda S, Neslund-Dudas C, Ritzwoller DP, Schottinger JE, Tiro JA, Vachani A, Doria-Rose VP

Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.
(2022 Oct)
Ann Surg Oncol 29(11): 7194-7201
Flanagan MR, Doody DR, Voutsinas J, Wu Q, Banda K, Sharifi N, Li CI, Gadi VK

Show complete publication list